AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Enovis Corporation operates as a medical technology company worldwide.
It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.
Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand.
The company was formerly known as Colfax Corporation.
Enovis Corporation is headquartered in Wilmington, Delaware.
Country | United States |
IPO Date | May 8, 2008 |
Industry | Industrial - Machinery |
Sector | Industrials |
Employees | 6,550 |
CEO | Matthew L. Trerotola |
Contact Details
Address: 2711 Centerville Road Wilmington, Delaware United States | |
Website | https://www.enovis.com |
Stock Details
Ticker Symbol | ENOV |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001420800 |
CUSIP Number | 194014502 |
ISIN Number | US1940145022 |
Employer ID | 54-1887631 |
SIC Code | 3842 |
Key Executives
Name | Position |
---|---|
Matthew L. Trerotola | Chief Executive Officer & Chairman |
Bradley J. Tandy J.D. | Senior Vice President & Chief Legal Officer |
Phillip Benjamin Berry | Senior Vice President & Chief Financial Officer |
Brady R. Shirley | Executive Advisor & Director |
Daniel A. Pryor | Executive Vice President of Strategy & Business Development |
Derek Leckow J.D. | Vice President of Investor Relations |
John Kleckner | Vice President, Controller & Chief Accounting Officer |
Katie Sweet | Vice President of Corporate Communication |
Patricia A. Lang | Senior Vice President & Chief Human Resources Officer |
Tim Czartoski | President of U.S. Surgical and Global Product & Enabling Technologies |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 13, 2025 | 8-K | Current Report |
Jan 03, 2025 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 13, 2024 | SCHEDULE 13G | Filing |
Nov 06, 2024 | 10-Q | Quarterly Report |
Nov 06, 2024 | 8-K | Current Report |
Oct 01, 2024 | 4 | Filing |
Aug 07, 2024 | 4 | Filing |
Aug 07, 2024 | 4 | Filing |
Aug 07, 2024 | 4 | Filing |